Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
Authors
Jason J. Luke
University of Chicago Comprehensive Cancer Center, Chicago, IL
Jason J. Luke, Sameer R. Ghate, Jonathan Kish, Choo Hyung Lee, Briana Ndife, Lindsay McAllister, Sonam Mehta, Antonio Reis Nakasato, Bruce A. Feinberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 141)
DOI
10.1200/JCO.2019.37.8_suppl.141
Abstract #
141
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients.
First Author: Sameer Ghate
Poster
2022 ASCO Annual Meeting
Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
First Author: Adriana Matutino Kahn
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Healthcare resource utilization in first-line immunotherapies for patients with metastatic melanoma.
First Author: Frank Xiaoqing Liu
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).
First Author: Jason J. Luke